Advertisement

Efficacy of perindopril in the treatment of systemic hypertension

  • Suzanne Oparil
    Correspondence
    Address for reprints: Suzanne Oparil, MD, University of Alabama, Birmingham, Ziegler Research Building, Room 1032, Birmingham, Alabama 35294
    Affiliations
    Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease, University of Alabama School of Medicine, Birmingham, Alabama, USA
    Search for articles by this author

      Abstract

      The angiotensin-converting enzyme inhibitor, perindopril erbumine, has been approved for use in the United States only recently but has been studied extensively worldwide over the last decade. Placebo-controlled trials in a wide range of patients with hypertension, including the elderly, those with isolated systolic hypertension, and those with concomitant diseases such as hyperlipidemia, diabetes, cardiac arrhythmia, peripheral arterial occlusive disease, nephropathy with proteinuria, and chronic obstructive pulmonary disease, have shown that perindopril is highly effective in lowering both systolic and diastolic blood pressure (BP). Studies in which BP has been monitored for 24-hour intervals show that perindopril (1) has a gradual onset of action, (2) provides smooth BP control over its once-daily dosing interval, (3) has a trough–peak ratio of about 1, and (4) maintains its antihypertensive efficacy despite missed doses. Perindopril increases arterial compliance and reverses left ventricular hypertrophy in hypertensive patients. Both of these effects are at least partly independent of its ability to lower BP. Perindopril is safe and well tolerated in patients with hypertension. Rates of adverse events and discontinuation because of such events are low.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burt V.L
        • Whelton P
        • Roccella E.J
        • Brown C
        • Cutler J.A
        • Higgins M
        • Horan M.J
        • Labarthe D
        Prevalence of hypertension in the US adult population.
        Hypertension. 1995; 25: 305-313
      1. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Arch Intern Med. 1997; 157: 2413-2446
      2. Carretero OA, Oparil S. Essential hypertension. Circulation 2000;101:329–355, 446–453.

        • Weber M.A
        Interrupting the renin-angiotensin system.
        Am J Hypertens. 1999; 12: 189S-194S
        • Schlaich M.P
        • Schmieder R.E
        Left ventricular hypertrophy and its regression.
        Am J Hypertens. 1998; 11: 1394-1404
        • Heart Outcomes Prevention Evaluation Study Investigators
        Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes.
        Lancet. 2000; 355: 253-259
        • Genoni M
        • Malacrida R
        • Sessa F
        • Siegrist P
        • Maggioni A.P
        • Moccetti T
        Long-term safety of an early ACE-inhibitor treatment of patients with acute myocardial infarction.
        Z Kardiol. 2000; 89: 81-83
        • Swedberg K
        • Kjekshus J
        • Snapinn S
        Long-term survival in severe heart failure in patients treated with enalapril.
        Eur Heart J. 1999; 20: 136-139
        • Chrysant S.G
        • McDonald R.H
        • Wright J.T
        • Barden P.L
        • Weiss R.J
        • Perindopril Study Group
        Perindopril as monotherapy in hypertension.
        Clin Pharmacol Ther. 1993; 53: 479-484
        • Sukonthasarn A
        • Ratanaprakarn R
        • Koanantakul B
        • Ngam-Ukos P
        Efficacy and acceptability of perindopril in essential hypertension.
        J Med Assoc Thai. 1994; 77: 281-287
        • Myers M.G
        • Perindopril Multicentre Dose-Response Study Group
        A dose-response study of perindopril in hypertension.
        Can J Cardiol. 1996; 12: 1191-1196
        • Mancia G
        • Giannattasio C
        • Turrini D
        • Grassi G
        • Omboni S
        Structural cardiovascular alterations and blood pressure variability in human hypertension.
        J Hypertens. 1995; 13: S7-S14
        • Lees K.R
        • Reid J.L
        • Scott M.G.B
        • Hosie J
        • Herpin D
        • Santoni J.-P
        Captopril versus perindopril.
        J Hum Hypertens. 1989; 3: 17-22
        • Alcocer L
        • Campos C
        • Bahena J.H
        • Nacaud A
        • Parra Carillo J
        • Calvo C
        • Weber C
        • Lerebours G
        • Mickalonis L
        • Villahermosa M.T
        Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension.
        Cardiovasc Drugs Ther. 1995; 9: 431-436
        • Yusoff K
        • Razak T.A
        • Yusof N
        • Rafee N.M
        Comparative efficacy of perindopril and enalapril once daily using 24-hour ambulatory blood pressure monitoring.
        Int J Clin Pract. 1999; 53: 277-280
        • Anderson A
        • Morgan O
        • Morgan T
        Effectiveness of blood pressure control with once daily administration of enalapril and perindopril.
        Am J Hypertens. 1994; 7: 371-373
        • Zannad F
        • Bernaud C.M
        • Fay R
        • General Physicians Investigators’ Group
        Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension.
        J Hypertens. 1999; 17: 137-146
        • Thurston H
        • Mimran A
        • Zanchetti A
        • Gretens G
        • Rorive G
        • Borwn C.L
        • Santoni J.P
        A double blind comparison of perindopril and atenolol in essential hypertension.
        J Hum Hypertens. 1990; 4: 547-552
        • Morgan T.O
        • Louis W.J
        • MacDonald G.J
        • Conway E.L
        • Bartholomeusz L.C
        • Anderson A.I.E
        • Cameron D.P
        • Donnelly T
        • Frewin D.B
        • Hooper M.J
        • et al.
        Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension.
        Am J Med. 1992; 92: 73S-78S
        • Andrejak M
        • Santoni J.P
        • Carre A
        • Deruyttere M
        • Magometschnigg D
        • Gotzen R
        • Stumpe K.O
        A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension.
        Fundam Clin Pharmacol. 1991; 5: 185-192
        • Chrysant S.G
        Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension.
        J Clin Pharmacol. 1997; 37: 47-52
        • Luccioni R
        • Sever P.S
        • DiPerri T
        • Redon J
        • Laurandin I
        • Brault Y
        • Chastang C
        • Gue
        • European Coordination Group
        An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension.
        J Hypertens. 1995; 13: 1847-1851
        • Suraniti S
        • Berrut G
        • Marre M
        • Fressinaud P
        Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients.
        Am J Cardiol. 1993; 71: 28E-31E
        • Castaigne A
        • Chalmers J
        • Morgan T
        • Chastang C
        • Feldmann L
        • Guez D
        Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination.
        Clin Exp Hypertens. 1999; 21: 1097-1110
        • Overlack A
        • Adamczak M
        • Bachmann W
        • Bonner G
        • Bretzel R.G
        • Derichs R
        • Krone W
        • Lederle R.M
        • Reimann H.J
        • Zschiedrich H
        • Stumpre K.O
        • Perindopril Therapeutic Safety Collaborative Research Group
        ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases.
        Am J Med. 1994; 97: 126-134
        • Bonner G
        • Lederle R.M
        • Scholze J
        • Stumpe K.O
        Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy.
        Drug Res. 1993; 43: 852-855
        • Haiat R
        • Piot O
        • Gallois H
        • Hanania G
        Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril.
        J Cardiovasc Pharmacol. 1999; 33: 953-959
        • Tan K.W
        • Leenen F.H.H
        Persistence of anti-hypertensive effect after missed dose of perindopril.
        Br J Clin Pharmacol. 1999; 48: 628-630
        • Kim S
        • Iwao H
        Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.
        Pharmacol Rev. 2000; 52: 11-34
        • Sihm I
        • Schroeder A.P
        • Aalkjaer C
        • Holm M
        • Morn B
        • Mulvany M
        • Thygesen K
        • Lederballe O
        Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
        Blood Press. 1995; 4: 241-248
        • Kool M.J
        • Lustermans F.A
        • Breed J.G
        • Struyker Boudier H.A
        • Hoeks A.P
        • Reneman R.S
        • Van Bortel L.M
        The influence of perindopril and the diuretic combination amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients.
        J Hypertens. 1995; 13: 839-848
        • Asmar R.G
        • Journo H.J
        • Lacolley P.J
        • Santoni J.P
        • Billaud E
        • Levy B.I
        • Safar M.E
        Treatment for one year with perindopril.
        J Hypertens. 1988; 6: S33-S39
        • Girerd X
        • Giannattasio C
        • Moulin C
        • Safar M
        • Mancia G
        • Laurent S
        Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients.
        J Am Coll Cardiol. 1998; 31: 1064-1073
        • Agabiti-Rosei E
        • Muiesan M.L
        • Rizzoni D
        Antihypertensive treatment and left ventricular hypertrophy.
        Ann Ital Med Int. 1993; 8: 97S-103S
        • Pancera P
        • Arosio E
        • Arcaro G
        • Priante F
        • Montesi G
        • Paluani F
        • Lechi A
        Haemodynamic parameters in hypertensive patients.
        J Hypertens Suppl. 1989; 7: S284-S285
        • Schulte K.-L
        • Meyer-Sabellek W
        • Liederwald K
        • van Gemmeren D
        • Lenz T
        • Gotzen R
        Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine.
        Am J Cardiol. 1992; 70: 468-473
        • Grandi A.M
        • Bignotti M
        • Gaudio G
        • Zanzi P
        • Guasti L
        • Venco A
        Ambulatory blood pressure and left ventricular changes during antihypertensive treatment.
        J Cardiovasc Pharmacol. 1995; 26: 737-741
        • Schwartzkopff B
        • Brehm M
        • Mudhenke M
        • Strauer B.E
        Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease.
        Hypertension. 2000; 36: 220-225
        • Speirs C
        • Wagniart F
        • Poggi L
        Perindopril postmarketing surveillance.
        Br J Clin Pharmacol. 1998; 46: 63-70
        • Degaute J.-P
        • Leeman M
        • Desche P
        Long-term acceptability of perindopril.
        Am J Med. 1992; 92: 84S-90S
      3. Arky R. Physicians’ Desk Reference. 55th ed. Montvale, NJ: Medical Economics, 2001.

        • Fox K.M
        • Henderson J.R
        • Bertrand M.E
        • Ferrari R
        • Remme W.J
        • Simoons M.L
        The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA).
        Eur Heart J. 1998; 19: J52-J55
        • Stumpe K.O
        • Ludwig M
        • Heagerty A.M
        • Kolloch R.E
        • Mancia G
        • Safar M
        • Zanchetti A
        • PROTECT Study Group
        Vascular wall thickness in hypertension.
        Am J Cardiol. 1995; 76: 50E-54E
        • Cleland J.G
        • Tendera M
        • Adamus J
        • Freemantle N
        • Gray C.S
        • Lye M
        • O’Mahoney D
        • Polonski L
        • Taylor J
        • PEP Investigators
        Perindopril for elderly people with chronic heart failure.
        Eur J Heart Fail. 1999; 1: 211-217
      4. Solvay Pharmaceuticals, Inc. Marietta, Georgia. Data on file.

        • Mansoor G.A
        • Massie B.M
        Left ventricular hypertrophy.
        Blood Press Monit. 1999; 4: S19-S22